Insights
Cell and Gene Therapy

Cell and Gene Therapy
With personalised cancer vaccines on the rise, is manufacturing scalable yet?

Life Science
How is cell and gene therapy innovation adapting to a changing investment landscape? Insights from TTP’s Cell & Gene panel event

Life Science
How can you prove 99.9% reliability? A challenge in automating and scaling cell therapies

Life Science
What failure rate are we willing to accept in cell therapy manufacture? Insights from medical device development

Life Science
Special Delivery: can advanced intracellular delivery enable superior cell therapies for solid tumour treatment – and beyond?

Life Science
Only a ‘click’ away: click chemistry transforms life science applications

Life Science
Driving Cell Therapy Innovation: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies

Life Science
Predicting failure rates in cell therapy manufacturing: is one in a million good enough?

Life Science
How many cells should a therapeutic cell sorter sort? (Part 3)

Life Science
Who should lead the charge in cell therapy manufacturing?

Life Science
How many cells should a therapeutic cell sorter sort? (Part 2)

Life Science
How many cells should a therapeutic cell sorter sort? (Part 1)
There are no insights for your current selection. Please select a different industry.